Top Medical News
3 days ago
Tenofovir disoproxil fumarate (TDF) for hepatitis B virus (HBV) infection suppresses hepatocellular carcinoma (HCC) risk better than entecavir, a new study has found.
6 days ago
Patients with chronic hepatitis B (CHB) virus infection who are HBeAg-negative are more likely to have advanced liver fibrosis than those with a positive HBeAg status, a study has found.
Stephen Padilla, 15 Jan 2020
Patients with nonalcoholic fatty liver disease (NAFLD) tend to consume more energy, macronutrients, added sugar and fructose than the controls, as shown in a Singapore study. Waist circumference and energy consumption, but not fructose intake, significantly correlate with NAFLD.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
04 Jan 2020
Hepatitis C virus (HCV) infection continues to be the leading indication of liver transplantation (LT) among patients with hepatocellular carcinoma (HCC), trailed by nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD), a recent study has found.
26 Dec 2019
Dietary intake of vitamins C and E may help protect against liver damage associated with nonalcoholic fatty liver disease (NAFLD), a recent study has shown.
25 Dec 2019
In patients with stable decompensated cirrhosis, galectin-3 may be an indicator of established chronic kidney disease (CKD), a recent study has shown.
Special Reports
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
Roshini Claire Anthony, 10 May 2019

Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress (ILC 2019) showed.

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Audrey Abella, 25 Apr 2019
Patients with chronic hepatitis B virus (HBV) infection treated with the nucleot(s)ide analogue tenofovir disoproxil fumarate (TDF) had a lower risk of hepatocellular carcinoma (HCC) than those treated with entecavir, according to data from a large observational study presented at ILC 2019.
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download